drugset / Trial / NCT05258136
Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical study on the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
Timeline
- Start
- 2021-06-01
- Primary completion
- 2023-06-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD20 monoclonal antibody | Monoclonal antibody | 100 mg/m2 | Intravenous |